Back to News
Market Impact: 0.2
UCB Partners With Cradle Therapeutics To Use AI In Antibody Drug Discovery
Source: Nasdaq
Healthcare & BiotechArtificial IntelligenceTechnology & Innovation
UCB SA entered a strategic collaboration with Cradle Therapeutics to use Cradle’s AI platform to design and refine therapeutic antibodies. The announcement provided no financial terms, development milestones, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
UCB0.60
More News
- What Wall Street billionaires are saying about Democrats' midterm sweep
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- Oil and data centre stocks sink after US midterms
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says